The World Health Organization (WHO) system lists five morphological categories of systemic mastocytosis (SM): indolent (ISM), smoldering, SM with an associated hematological neoplasm (SM-AHN), aggressive (ASM) and mast cell leukemia (MCL). Recent studies have highlighted the prognostic importance of mutations in SM, including ASXL1, RUNX1, and SRSF2. In contrast, information on incidence of cytogenetic abnormalities in SM and their prognostic relevance, especially in the context of mutations, is limited. In the current study, we retrospectively reviewed the cytogenetic findings in 348 consecutive cases of SM (median age 59 years; 53% males); 41% constituted ISM, 45% SM-AHN, 14% ASM and two cases of MCL. Karyotype was abnormal in 53 (15%) cases with incidences of 6% for ISM, 26% for SM-AHN and 8% for ASM (P < .001); among SM-AHN cases, abnormal karyotype incidences were 0% for SM-AHNlymphoid and 28% for SM-AHN-myeloid (P < .001). Clinical correlative studies disclosed significant associations between abnormal karyotype and male sex (P = .002), age > 60 years (P = .04), thrombocytopenia (P < .001) and anemia (P < .001), but not with the presence of adverse mutations (P = .19). In univariate analysis, abnormal karyotype was associated with inferior survival (HR 3.0, 95% CI 2.0-4.3), specifically confirmed for ASM (HR 4.9, 95% CI 1.1-16.1) and SM-AHN (HR 1.8, 95% CI 1.2-2.7). Sample size adequacy allowed additional multivariable analysis in SM-AHN-myeloid, which disclosed independent prognostic contribution from adverse mutations (P = .003), anemia (P = .003) and thrombocytopenia (P = .001), but not from abnormal karyotype (P = .31). Our observations suggest that mutations are prognostically more relevant than karyotype in SM. In the particular study, abnormal karyotype was reported in 15% of the patients, all occurring in the SM-AHN category, with 22%
| INTRODUCTION
The World Health Organization (WHO) system lists five morphological categories of systemic mastocytosis (SM): indolent (ISM), smoldering (SSM), SM with an associated hematological neoplasm (SM-AHN), aggressive (ASM) and mast cell leukemia (MCL); 1 the latter three are operationally grouped together as "advanced SM." The occurrence of clonal chromosomal abnormalities in SM has been recognized as early as 1987. 2 In the most recent and so far largest study on the subject matter, 3 the authors analyzed cytogenetic and mutation studies in 109 patients with SM, including 26 indolent and 83 advanced cases.
In the particular study, abnormal karyotype was reported in 15% of the patients, all occurring in the SM-AHN category, with 22%
incidence. 3 The authors reported higher risk of leukemic transformation and shorter survival, especially in advanced SM with poor-risk karyotype, and independent of somatic mutations. 3 Recent studies have highlighted the prognostic importance of mutations in SM, including ASXL1, RUNX1, and SRSF2. [4] [5] [6] Obviously, there is a need for further clarification on the prognostic relevance of karyotype in SM, and its prognostic interaction with high risk mutations. Over the last several decades, we have assembled a large cohort of patients with SM seen at our institution; in the current study, we retrospectively reviewed the cytogenetic findings in 348 informative cases of SM, in order to clarify incidence and prognostic impact of abnormal karyotype, stratified by WHO morphologic subcategories; a subset of these patients were also studied for mutations. No of C findings; median (range)
Number of B findings; median (range) 7 Cytogenetic analysis in all instances was performed on fresh bone marrow aspirates, placed in hypotonic trypsin-colcemid solution and processed according to standard techniques for chromosome analysis using GTL banding with trypsin and Leishman stain. 8 Thrombolytic agents were added to clotted bone marrow specimens in order to improve success rates. 9 Chromosomal abnormalities were considered clonal if the same structural abnormality or extra chromosome appears in at least two and monosomy in at least three metaphases. 7 It should be noted that cytogenetic abnormalities may have (Table 1) .
Karyotype was abnormal in 53 (15%) cases and included unfavorable (n = 29; 8%) and favorable (n = 24; 7%) abnormalities (Table 2) .
Abnormal karyotype incidences were 6% for ISM and 22% for advanced SM (P < .001). Among advanced SM cases, abnormal karyotype incidences were 26% for SM-AHN and 8% for ASM (P < .001);
one of 2 MCL cases displayed abnormal karyotype. Among SM-AHN cases, abnormal karyotype incidences were 0% for SM-AHN-lymphoid, 28% for SM-AHN-myeloid (P < .001); the latter included 19%
for SM-CMML, 21% for SM-MDS/MPN, 23% for SM-MPN, 36% for SM-MDS and 41% of SM-myeloid-unclassified (P < .001). Clinical correlative studies disclosed significant associations between abnormal karyotype and male sex (P = .002), age > 60 years (P = .04), thrombocytopenia (P < .001) and anemia (P < .001), but not with the presence of adverse mutations (P = .19). Figure 1A ) and significance was sustained when analysis was adjusted for two-tiered (advanced vs 
| DISCUSSION
The WHO disease category of SM is morphologically and clinically heterogeneous and the current study shows similar diversity in karyotype. As outlined in Table 1 , cytogenetic abnormalities are infrequently encountered (<10% incidence) in patients with ISM and ASM while their incidence might exceed 25% in SM-AHN. In regards to the latter, the current study underscores the need to distinguish between SM-AHNmyeloid and SM-AHN-lymphoid in describing the incidence of cytogenetic abnormalities in SM; incidence was 0% in the latter and 28% in the former. Incidence figures in SM-AHN-myeloid did not appear to be affected by the specific myeloid neoplasm component; that is incidence figures were similar between SM-CMML (19%), SM-MPN (23%), SM-MDS (36%), SM-MDS/MPN (21%), and SM-myeloid unclassified (41%).
Although it is the largest study to date of its kind, we caution against drawing definitive conclusions from the current study because of the relatively small number of informative cases in disease subcategories, including ISM, ASM, and MCL. However, the current study confirms the infrequent occurrence of cytogenetic abnormalities, in the absence of an associated another hematologic malignancy (ie, in ISM and ASM), although the additional observation regarding prognostic relevance requires validation in a larger study, which will probably require multi-center collaboration. On the other hand, the number of informative cases in SM-AHN-myeloid was sufficient enough to examine its prognostic interaction with mutations and other previously established risk factors. 4, 5, 11, 12 In this regard, we found the prognostic contribution of abnormal karyotype in SM-AHN-myeloid, which was apparent in univariate analysis, to be undermined by that of adverse mutations, anemia and thrombocytopenia. Also, we found no correlation between abnormal karyotype and adverse mutations while anemia and thrombocytopenia were significantly associated with abnormal karyotype.
Additional studies with larger number of informative cases are necessary in order to decipher the issue at hand further in the context of specific myeloid neoplasms (eg, SM-MPN, SM-CMML, SM-MDS, etc.). In a recent study, 13 we compared the clinical and laboratory features of 501 patients with CMML and 50 with SM-CMML; 22% of patients with SM-CMML harbored abnormal karyotype and mutations involving TET2 (62%), ASXL1 (35%), SRSF2 (27%), RUNX1 (14%), and other genes. As was the case in the current study, in the aforementioned study, 13 we found mutations to be prognostically more rele- 
